{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:54:16Z","timestamp":1781585656213,"version":"3.54.5"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100002101","name":"Division of Health Sciences, University of Otago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA040460"],"award-info":[{"award-number":["R01DA040460"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Synthetic cannabinoids remain one of the most prominent classes of New Psychoactive Substances (NPS). The introduction of \u201cblanket bans\u201d has only invigorated the development and emergence of novel compounds. Recently, a putative synthetic cannabinoid, AB\u2010MDMSBA, was identified in Australia and New Zealand, with little to no pharmacological data on this compound. This current study, therefore, aimed to determine the potential activity of AB\u2010MDMSBA at the human cannabinoid CB\n                    <jats:sub>1<\/jats:sub>\n                    receptor. Results revealed AB\u2010MDMSBA failed to activate cAMP and \u03b2\u2010arrestin 2 pathways, or to induce a conformational change in a CB\n                    <jats:sub>1<\/jats:sub>\n                    biosensor, unlike the known synthetic agonist AMB\u2010FUBINACA, suggesting the compound is not a synthetic cannabinoid. These findings may aid in drug classification and the identification of structurally similar compounds.\n                  <\/jats:p>","DOI":"10.1002\/prp2.70278","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:22:00Z","timestamp":1780978920000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["<scp>AB<\/scp>\n                    \u2010\n                    <scp>MDMSBA<\/scp>\n                    \u2014Not a Synthetic Cannabinoid Receptor Agonist"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2686-7246","authenticated-orcid":false,"given":"Monica","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology University of Otago  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharshini","family":"Ganeshan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology University of Otago  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izzy","family":"Horgan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology University of Otago  Dunedin New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4255-0548","authenticated-orcid":false,"given":"Hannah","family":"Partington","sequence":"additional","affiliation":[{"name":"New Zealand Institute for Public Health and Forensic Science (PHF Science)  Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5997-6898","authenticated-orcid":false,"given":"Michelle","family":"Glass","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology University of Otago  Dunedin New Zealand"},{"name":"New Zealand Institute for Public Health and Forensic Science (PHF Science)  Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"United Nations Office on Drugs and Crime World Drug Report 2025 2025accessed at January 16 2026 https:\/\/www.unodc.org\/unodc\/en\/data\u2010and\u2010analysis\/wdr\u2010drug\u2010market\u2010patterns\u2010trends.html."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.DRUGALCDEP.2025.112698"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2025.106431"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100460"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1021\/ACSCHEMNEURO.9B00429"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113871"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116052"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.BCP.2019.08.025"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/DTA.3422"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/S00204\u2010025\u201004191\u20100"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJPHAR.2024.176549"},{"key":"e_1_2_10_13_1","unstructured":"Home Office Review of the Psychoactive Substances Act 2016 2018accessed at https:\/\/assets.publishing.service.gov.uk\/media\/5beec777e5274a2b0fd695db\/Review_of_the_Psychoactive_Substances_Act__2016___web_.pdf."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/BCP.14168"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/20503245221138735"},{"key":"e_1_2_10_16_1","unstructured":"Drug Information and Alerts Aotearoa New Zealand New synthetic cannabinoid misrepresented as a benzodiazepine. High Alert 2025accessed at January 6 2026 https:\/\/www.highalert.org.nz\/alerts\u2010and\u2010notifications\/new\u2010synthetic\u2010cannabinoid\u2010misrepresented\u2010as\u2010a\u2010benzodiazepine\/."},{"key":"e_1_2_10_17_1","unstructured":"National Centre for Clinical Research on Emerging Drugs Synthetic cannabinoid AB\u2010MDMSBA found in \u2018benzodiazepine\u2019 samples. The Know 2024accessed at January 6 2026 https:\/\/theknow.org.au\/alerts_warnings\/synthetic\u2010cannabinoid\u2010ab\u2010mdmsba\u2010found\u2010in\u2010benzodiazepine\u2010samples\/."},{"key":"e_1_2_10_18_1","unstructured":"Cayman Chemical AB\u2010MDMSBA. Cayman Chemical 2026accessed at January 15 2026 https:\/\/www.caymanchem.com\/product\/41967\/ab\u2010mdmsba."},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.BMCL.2006.09.049"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/ACSSENSORS.4C03589"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/BPH.13866"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/BPH.12329"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M609695200"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/BPH.15973"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/FPSYT.2022.1048836\/BIBTEX"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1124\/PHARMREV.123.001028\/\u2010\/DC1"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2022.2028203"},{"key":"e_1_2_10_28_1","unstructured":"New Zealand Drug Foundation What we saw at drug checking in 2024 2024accessed at January 16 2026 https:\/\/drugfoundation.org.nz\/assets\/PageBlocks\/Downloads\/What\u2010we\u2010saw\u2010at\u2010drug\u2010checking\u2010in\u20102024\u2010NZ\u2010Drug\u2010Foundation.pdf."},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/ADD.15734"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.70278","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.70278","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.70278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:18:57Z","timestamp":1781583537000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.70278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/prp2.70278"],"URL":"https:\/\/doi.org\/10.1002\/prp2.70278","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2026-02-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70278"}}